Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01773785 |
|
Recruitment Status :
Terminated
(The study completed the first phase and did not meet efficacy end point to enter into the randomized phase.)
First Posted : January 23, 2013
Last Update Posted : October 13, 2021
|
Sponsor:
Spectrum Pharmaceuticals, Inc
Information provided by (Responsible Party):
Spectrum Pharmaceuticals, Inc
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | September 2015 |
| Actual Study Completion Date : | September 2015 |
| Certification/Extension First Submitted : | September 30, 2021 |